Summit Therapeutics (SMMT) Non-Current Assets (2018 - 2026)

Summit Therapeutics (SMMT) has reported Non-Current Assets for 9 consecutive years, with $31.6 million the latest figure, recorded in Q2 2026.

• Quarterly Non-Current Assets rose 113.6% year-over-year to $31.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $109.0 million (up 108.67% YoY) and the FY2025 annual result came in at $30.9 million, up 161.48% from the prior year.
• Non-Current Assets climbed to $31.6 million in Q2 2026 per SMMT's latest filing, from $31.3 million in the prior quarter.
• Over the last five years, Non-Current Assets for SMMT reached as high as $31.6 million in Q2 2026 and fell as low as $6.9 million in Q1 2023.
• A 5-year average of $16.1 million and a median of $13.5 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets sank 59.68% — and 2025, when it jumped 161.48%.
• Year by year, Non-Current Assets stood at $7.5 million in 2022, then soared by 77.53% to $13.2 million in 2023, then fell by 10.78% to $11.8 million in 2024, then surged by 161.48% to $30.9 million in 2025, then advanced by 2.35% to $31.6 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $31.6 million, $31.3 million, and $30.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.